Retatrutide 10mg
Retatrutide (LY3437943) is a triple GIP/GLP-1/Glucagon receptor agonist — activating all three key metabolic hormone receptors in a single molecule. Developed by Eli Lilly, it represents the leading edge of incretin-based metabolic research, with Phase 2 clinical data reporting mean weight reductions exceeding 24%.
By adding glucagon receptor agonism to the GIP/GLP-1 combination, retatrutide promotes hepatic lipid oxidation, thermogenesis, and energy expenditure beyond what is achievable with dual agonists — making it a critical research tool for obesity biology and metabolic syndrome studies.
Specifications: 10mg lyophilized powder | Purity ≥99% (HPLC) | Store at −20°C
For Research Use Only. Not for human or veterinary use. This product is intended solely for in vitro and laboratory research. Not approved by the FDA. Not a drug, food, or cosmetic. Keep out of reach of children.
